UNSPSC 51123102: Acecainide hydrochloride

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C15H23N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B9K738KX14, chemically known as benzamide, 4-(acetylamino)-n-(2-(diethylamino)ethyl)-, monohydrochloride but more generally known as acecainide hydrochloride, which bears US NIH Compound Identifier 71417. The base compound, acecainide, also comes in base form. Most nations, for tariff and trade purposes, schedule acecainide hydrochloride under HS 29242995 and SITC 51479.

As of Q4 2014, ACECAINIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Acecainide hydrochloride bears US NLM identifiers UMLS ID C0282038 and NCI Concept Code C75126. SMILES: CCN(CC)CCNC(=O)C1CCC(CC1)NC(=O)C.CL.

UNSPSC 51123102 Acecainide hydrochloride, a Commodity-tier code, captures pharmaceutical procurement by state and local health agencies, primarily for emergency medical services and pharmacy benefit programs. State and local governments solicit this and related advanced life support medications through formal competitive bid processes targeting fire departments, emergency medical services, and state health benefit administrators. The solicitations emphasize strict compliance with FDA manufacturing standards, Drug Supply Chain Security Act (DSCSA) certifications, cGMP requirements, and OSHA Hazard Communication Standards for all supplied products, with vendors responsible for maintaining inventory management, expiration-date warranties, and pickup-and-replacement protocols to ensure continuous availability of critical medications.

Recent activity spans fire departments, state health agencies, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications to support Tampa Fire Rescue with a response deadline of April 8, 2026 and estimated contract value of $40,000.00, featuring a 5 percent SLBE bid discount and one-year initial term with renewal options. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. Activity is concentrated in Texas, Minnesota, Florida, and states participating in regional cooperative purchasing networks, with solicitations typically requiring award within 90–120 days and initial contract terms of one to two years with renewal or extension options.